

## **Remicade and Biosimilars Order Form**

Phone: (877) 246-9104 Fax: (800)-783-9146

WWW.Biotekrx.com

PATIENT INFORMATION		
Patient Name:	Date:	
Address:		
City, State, Zip:		
	Disk dis (Oinste sus)	
DOB: Weight: Height:	Diabetic (Circle one): Yes / No	
Diagnosis / ICD 10 Code:	Allergies:	
	CHANGE OF INTERVAL	☐ CHANGE OF PROVIDER
If the patient cannot provide recent PPD results (within12 months), then perforn		
TUBERCULOSIS SCREENING: PPD Date Performed:		
<ul> <li>□ PPD results provided by patient per Dr.</li> <li>Result: □ Negative → May Initiate Remicade® Therapy</li> </ul>	Date:	<del></del>
Positive → □ Chest X-Ray performed Date Performed:	☐ Negative result → May ini	tiata Ramicada®
□ 1 Oslave → □ Onest X-ray performed Date 1 errormed.	Positive result → TB treat	
☐ RN to teach disease management	E i coluve room.	
Remicade <sup>®</sup> - Choose Regimen: ☐ Remicade ☐ Avsola	☐ Inflectra ☐ Renflexi	s
☐ 3 mg/kg mg/NS 0.9% 250 mL or 500 mL of normal saline IV over 2 hours		
☐ 5 mg/kg mg/NS 0.9% 250 mL or 500 mL of normal saline IV over 2 hours	☐ Concomitant po Methotrexate	
☐ 10 mg/kg mg/NS 0.9% 250 mL IV over 2 hours	(Methotrexate RX given to Patient)	
☐mg/kgmg/NS 0.9% 250 mL or 500 mL of normal saline IV over 2 hours ☐ Repeat dose in 2 weeks and then every 6 weeks	☐ Infuse at weeks 0,2, and 6 then ev	ery 8 weeks
Duration of Therapy: $\Box$ x 1 year	☐ Other frequency:	
Other:		00 1 11 100 1 1 10 11 1
* Start infusion at 10 mL/hr. Double the rate after 15 minutes (as tolerated) for the first hour of infusion. (After first 15 minutes → 20 mL/hr, at 30 minutes → 40 mL/hr, at 45 minutes → 80 mL/hr, at 1 hr →160 mL/hr). At 90 minutes into the infusion, the rate may be increased for the last time to a maximum rate of 250 mL/hr.		
Pre-Medications:		
☐ Diphenhydraminemg, po -or- IV (circle one), prior to start of infu	usion	
☐ Acetaminophen 650 mg po prior to start of infusion		
□ <b>Prednisone</b> mg, po -or- □ Methylprednisolone 40 mg IVP -or- □ Hydrocortisone 100 mg IVP		
□ Other:		
* Administer pre-medications 15 to 30 minutes prior to start of infusion *		
IV Access:		
☐ Start PIV if no IV access available ☐ Maintain current central line access		
Catheter Care:		
☐ Sodium Chloride 0.9% mL IV before and after each IV access and PRN per protocol		
☐ Sodium Chloride 0.9% mL as above <b>AND</b> Heparin 100 Units /mL mL IV flush after second saline flush and PRN		
* Dressing changes weekly and PRN * Antimicrobial dressing P		4
* May obtain blood from IV access for labs	mL sterile water IVP 2 mL per lumen; N	lay repeat after 2 nours x 1
□ CBC q □ CMP q □ CRP q □ ESR q _		ay Other
Standard Orders for Side Effects:		dy
☐ <b>Promethazine</b> 25 mg − 1-2 tabs po q 4-6 hrs PRN nausea / vomiting	☐ <b>Diphenhydramine</b> 25 mg - 1 to	2 caps po PRN
☐ <b>Acetaminophen</b> 325 mg - 2 tabs po q 4-6 hrs PRN HA, myalgia, fever	☐ Diphenhydramine 25 mg -or- 5	
☐ <b>Promethazine</b> 25 mg IV/IM <b>x</b> 1 dose PRN nausea / vomiting	☐ Other:	
Monitoring Parameters:		
☐ Obtain vital signs and temperature q 15 mins for the 1 <sup>st</sup> hour, then q 30 r	nins for the remainder of the infusion	
□ Observe patient for 30 mins following the infusion		
☐ Instruct patient to report symptoms of chills, fever, headache, sore throat	, pain, etc.	
☐ Other:Anaphylactic Reaction (AR):		
Epinephrine (based on patient weight)		
EpiPen® Auto-injector 0.3 mg (1:1000) - Inject IM <b>-or-</b> SubQ to patients who weigh ≥ 66 lbs (≥ 30 kg); may repeat in 3-5 mins <b>x</b> 1 if necessary		
EpiPen Jr® Auto-injector 0.15mg (1:2000) - Inject IM <b>-or-</b> SubQ to patients who weigh 33 - 66 lbs (15-30 kg): may repeat in 3-5 mins <b>x</b> 1 if necessary		
<b>Diphenhydramine</b> 50mg (1mL) - Give 50 mg slow IVP, administer IM if no IV access; may repeat <b>x</b> 1 after 10 mins, if necessary		
Hydrocortisone 100mg - Give 100 mg IVP -or- IM if no IV access		
Sodium Chloride 0.9% 500 mL infuse IV at a rate of 30 mL/hr		
Other Orders:		
Prescribing Physician: Address:		Phone:

PHYSICIAN'S SIGNATURE:

DATE:

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited.

If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such